BioSpace News Archive

Acquires Orphan Drug Designation for betahistine for the treatment of obesity associated with Prader-Willi syndrome (PWS)

Analyst Jason McCarthy, PhD of Maxim Group updated coverage on Soligenix, Inc. on December 6, 2018. For more information, please visit www.maximgrp.com.

ADCT-402 (loncastuximab tesirine) continues to demonstrate acceptable safety profile and anti-tumor activity in patients with relapsed or refractory diffuse large B-cell lymphoma; data from 183-patient study supports continued evaluation in ongoing pivotal Phase II trial

Dermavant Sciences today announced that the company will present new data on cerdulatinib during the 3rd Annual Inflammatory Skin Disease Summit (ISDS) taking place Dec. 12-15, 2018, in Vienna, Austria.

Resulting new tests will help researchers investigate links between gut microbiota and diabetes and obesity

International medical imaging IT and cybersecurity company Sectra (STO: SECT B) is growing in the medical IT and cybersecurity markets through collaboration with new and existing customers.

GB Sciences, Inc. (OTCQB: GBLX) announces on November 19, 2018, the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, on behalf of the Louisiana State University Agricultural Center, entered into a Master Research and Development Agreement with GB Sciences Louisiana, LLC.

MassRoots, Inc. is pleased to announce that MassRoots has acquired the WeedPass.com domain, where cannabis consumers can now locate dispensaries participating in the WeedPassTM Rewards Program and earn rewards for their purchases.

GLATECTTM (glatiramer acetate injection) is now the only glatiramer-based treatment covered by BC PharmaCare for the treatment of relapsing-remitting multiple sclerosis (RRMS).

Cardinal Health today announced that its board of directors has elected J. Michael Losh as an independent director effective December 5. Losh will serve as the chairman of the Audit Committee.